Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 24, 2026CureusOpen Access

Targeted Therapy in Erdheim-Chester Disease: A Case Report and Review of the Literature

View Full Paper
Ask AI
Bookmark
Share

Authors

AAAmmar AlromdhanYAYagnapriya AmmakolaGSGonzalo Cantu Soriano

Discussion

Loading...

Member takes

Overview

Case report demonstrates targeted therapy effectiveness in Erdheim-Chester disease, highlighting molecular profiling implications.

Key Points

  • To highlight the clinical presentation and treatment approach for Erdheim-Chester disease using targeted therapy.
  • Reported the case of a 39-year-old male with severe headaches and imaging findings.
  • Performed histopathological evaluation and molecular testing for BRAF mutations.
  • Administered targeted therapy with the BRAF inhibitor vemurafenib, monitoring for side effects.
  • The patient maintained a stable disease course at one-year follow-up.
  • Histopathology showed foamy histiocytes consistent with Erdheim-Chester disease.
  • The treatment led to manageable dermatologic toxicity with dose adjustments.

Cite This Study

Alromdhan et al. (2026) studied this question.

synapsesocial.com/papers/6a1295ae48a0ea1665671e43https://doi.org/10.7759/cureus.109423
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Case report: Targeted treatment strategies for Erdheim-Chester disease2024 · 6 citations
  2. 2EP14.04 ERDHEIM-CHESTER DISEASE WITH CENTRAL NERVOUS SYSTEM INVOLVEMENT: A RARE CASE REPORT2025
  3. 3An effective treatment in Erdheim Chester disease: vemurafenib: a case report2023
  4. 4Clinical Images: Erdheim–Chester disease presenting with fever, enlarged lymph nodes, and monoallelic <scp>BRAF</scp> ( <scp>V600E</scp> ) mutation2026
  5. 5Challenging Management of Erdheim-Chester Disease: A Case Report2024